Print

Lay Description

This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer than radiation alone.

Category

  • Cancers and Other Neoplasms
  • Mens Health
  • Prostate
IRB Number
20180809HU
NCT Number
NCT03371719
Open to Enrollment
Yes

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Regulatory Point of Contact
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu

Regulatory Point of Contact
Chethan Ramamurthy
(210) 450-1667
ramamurthyc@uthscsa.edu

Regulatory Point of Contact
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu

Local Recruitment Point of Contact
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu

Local Recruitment Point of Contact
Chethan Ramamurthy
(210) 450-1667
ramamurthyc@uthscsa.edu

Local Recruitment Point of Contact
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu

Principal Investigator
Chethan Ramamurthy